Vaughan, Ontario – Bausch + Lomb Corp. has launched as a publicly traded company.
The global eye health now trades under the “BLCO” symbol on the New York Stock Exchange and Toronto Stock Exchange.
“Today marks a tremendous milestone for Bausch + Lomb and an important step forward on the path to an independent company focused on eye health,” said Joseph C. Papa, chairman and CEO of Bausch + Lomb. “Bausch + Lomb has long been associated with many of the most significant advances in eye health, and I am honored to work alongside our 12,000 global employees as we continue to focus on achieving our ongoing mission of helping people see better to live better all over the world.”
The Financial Times noted that the company “had been aiming to raise up to $840mn” but that the pricing was scaled back to $18 per share and $630 million was raised.
Bausch + Lomb offers a portfolio of more than 400 products spanning contact lenses, lens and eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
